TABLE 2.
Demographic characteristics and treatments during acute infection
| N (/22) | Percentage | |
| Female sex | 8 | 36.40 |
| Hypertension | 12 | 54.50 |
| Diabetes mellitus | 6 | 27.30 |
| Dyslipidemia | 4 | 18.20 |
| Ischemic heart disease | 1 | 4.50 |
| Obesity | 3 | 13.60 |
| Drug treatment | ||
| ACEi | 4 | 18.20 |
| ARB | 4 | 18.20 |
| Beta-blockers | 3 | 13.60 |
| CCB | 4 | 18.20 |
| Diuretics | 3 | 13.60 |
| Alfa-blockers | 1 | 4.50 |
| Thyroid hormone | 2 | 9.10 |
| PPI | 3 | 13.60 |
| ASA | 4 | 18.20 |
| Statin | 3 | 13.60 |
| Smoking (active/former) | 9 | 40.90 |
| noninvasive mechanical ventilation (NIMV) | 8 | 36.40 |
| Thrombotic events (i.e. stroke, PE) | 6 | 27.30 |
| Antiviral drug | 11 | 50.00 |
| Hydroxychloroquine | 22 | 100.00 |
| Steroids | 14 | 63.60 |
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ASA, acetylsalicylic acid; CCB, calcium channel blocker; PE, pulmonary embolism; PPI, proton pump inhibitors.